• Mashup Score: 60

    On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.)

    Tweet Tweets with this article
    • 🚨🔥@OncoAlert Hot Off The Press 1/2 @US_FDA granted #accelerated approval to #Telisotuzumab-Vedotin for: ⭐️ #Patients with advanced non-squamous non-small cell #LungCancer AND: ✅#High #cMet overexpression ✅Received a prior systemic therapy 👇🏻 https://t.co/eqdgw8DxzW https://t.co/ZQHqvlNkRz

  • Mashup Score: 60

    On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.)

    Tweet Tweets with this article
    • 🚨🔥@OncoAlert Hot Off The Press 1/2 @US_FDA granted #accelerated approval to #Telisotuzumab-Vedotin for: ⭐️ #Patients with advanced non-squamous non-small cell #LungCancer AND: ✅#High #cMet overexpression ✅Received a prior systemic therapy 👇🏻 https://t.co/eqdgw8DxzW https://t.co/ZQHqvlNkRz